An interventional study of OrthoCor Active System in Pain, sponsored by Caerus Corporation. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by Caerus Corporation · Not applicable, Interventional, and Treatment
This is a prospective, multi-center, randomized, pivotal study to evaluate the OrthoCor Active System in individuals prescribed its use in comparison with the standard of care intervention for pain relief.
According to the Centers for Disease Control and Prevention, 50 million adults in the United States have chronic daily pain, with 19.6 million adults experiencing high impact chronic pain that interferes with daily life or work activities. Clinical best practices may recommend a collaborative, multimodal, multidisciplinary, patient-centered approach to treatment for various acute and chronic pain conditions to achieve optimal patient outcomes. For improved functionality, activities of daily living, and quality of life, clinicians are encouraged to consider and prioritize, when clinically indicated, nonpharmacologic approaches to pain management.
An alternative treatment option can be the use of restorative therapies. Restorative therapies play a significant role in acute and chronic pain management, and positive clinical outcomes are more likely if restorative therapy is part of a multidisciplinary treatment plan following a comprehensive assessment.
The OrthoCor Active System uses specialized Pulsed Electromagnetic Field (PEMF) technology to relieve pain and reduce edema through safe, clinically proven therapy. PEMF is a low-level, time-varying electromagnetic field that penetrates superficial soft tissue, helping to accelerate the body's natural anti-inflammatory and recovery responses. Inside every OrthoCor Active System is proprietary electronic circuitry that delivers PEMF to the source of injuries. PEMF has been shown to stimulate reaction pathways that result in pain and inflammation reduction. OrthoCor's patented PEMF accelerates the binding of calcium (Ca2+) to calmodulin (CaM), the process responsible for the body's natural, antiinflammatory nitric oxide (NO) cascade. NO is a key element in the body's natural healing process. It is also a vasodilator, increasing blood and lymphatic flow. Additionally, NO down-regulates interleukin-1 beta (IL1β) and inducible nitric oxide synthase (iNOS), which leads to reduced cyclooxygenase-2 (COX-2) and prostaglandins - molecules responsible for causing inflammation and pain. Unlike other systemic COX-2 inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), OrthoCor's targeted PEMF signals stimulate localized reaction pathways, thereby reducing pain and inflammation without the risks and side effects associated with NSAIDs.
In previous clinical studies, OrthoCor Active System was clinically proven to reduce pain, swelling and provide lasting relief without the use of pain medications or invasive procedures. OrthoCor Medical Inc. conducted a prospective, double blind, placebo controlled, randomized pilot study (2014-2016), enrolling 80 patients with Kellgren-Lawrence knee arthritis who used the OrthoCor knee system, which showed a significant 60% reduction in the mean pain score within the first 3 days of use compared with the sham group 2. A preliminary study conducted by OrthoCor Medical Inc. in 33 patients suffering from knee osteoarthritis utilizing the OrthCor knee system, showed reduced pain and stiffness after 15 days of treatment with a 43% reduction in pain score and a 79% improvement in activity limitations, symptoms, emotions, and overall quality of life.
The OrthoCor Active System is a portable (battery operated) non-invasive shortwave diathermy medical device which applies electromagnetic energy at a radio frequency (RF) of 27.12 MHz for the treatment of pain in superficial soft tissue, such as in the ankle, back, knee, wrist, elbow, shoulder, foot, or neck. The OrthoCor Active System delivers the pulsed RF signal of 6.5+0.5 Ws/cm3 to the tissue target via the inductive coupling with an applicator coil. The system also uses disposable, single-use, air activated OrthoPods that provide heat for the temporary relief of minor muscular \& joint aches \& pains associated with overexertion, strains, sprains, and arthritis.
The objective of this study is to evaluate the OrthoCor Active System in individuals presenting with post-operative pain and edema in superficial soft tissue. The OrthoCor Active System will be compared to the SOC intervention.
Caerus Corporation is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
OrthoCor Active System used for pain relief
Device: OrthoCor Active System
standard of care: over-the-counter pain medication
The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
Primary Safety EndPoint
Number of participants with adverse events
Time frame: after 2 weeks of use
Primary Efficacy EndPoint
Change from baseline of Mankoski pain scale between OrthoCor and standard of care. The Mankoski pain scale ranges from 0 representing no pain to 10 representing pain causing unconsciousness.
Time frame: at baseline compared to during 2 weeks of use
| Milestone | OrthoCor Active System | Standard of Care |
|---|---|---|
| Started | 59 | 61 |
| Completed | 48 | 43 |
| Not completed | 11 | 18 |
Number of participants with adverse events
| Participants | OrthoCor Active System | Standard of Care |
|---|---|---|
| Primary Safety EndPoint | 2 | 2 |
Change from baseline of Mankoski pain scale between OrthoCor and standard of care. The Mankoski pain scale ranges from 0 representing no pain to 10 representing pain causing unconsciousness.
| score on a scale | OrthoCor Active System | Standard of Care |
|---|---|---|
| Primary Efficacy EndPoint | -1.8 (-2.1 to -1.5) | -0.5 (-0.8 to -0.1) |
Collected over 2 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OrthoCor Active System | 0/59 (0%) | 0/59 (0%) | 2/59 (3.4%) |
| Standard of Care | 0/61 (0%) | 0/61 (0%) | 2/61 (3.3%) |
| Event | OrthoCor Active System | Standard of Care |
|---|---|---|
| tinglingSurgical and medical procedures | 1/59 | 0/61 |
| difficulty bending kneeSurgical and medical procedures | 1/59 | 0/61 |
| shoulder painSurgical and medical procedures | 0/59 | 1/61 |
| sleepinessSocial circumstances | 0/59 | 1/61 |
The numbers represent the ITT because the analyses for PP and ITT are very similar.
| Age, Continuous(years) | OrthoCor Active System | Standard of Care | Total |
|---|---|---|---|
| Mean | 54.0 ± 16.3 | 56.5 ± 16.2 | 55.3 ± 16.2 |
| Sex: Female, Male(Participants) | OrthoCor Active System | Standard of Care | Total |
|---|---|---|---|
| Female | 39 | 39 | 78 |
| Male | 20 | 22 | 42 |
| Race (NIH/OMB)(Participants) | OrthoCor Active System | Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 18 | 19 | 37 |
| White | 31 | 39 | 70 |
| More than one race | 5 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | OrthoCor Active System | Standard of Care | Total |
|---|---|---|---|
| United States | 59 | 61 | 120 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Caerus Corporation